Parabilis reveals IPO plans the day after Regeneron deal as listings heat up

Parabilis Medicines, the decade-old and well-funded "undruggable" biotech out of Greg Verdine's Harvard lab, seeks to become the 12th drug developer to conduct an initial public offering this year. The biotech